Entacapone
- Generic Name
- Entacapone
- Brand Names
- Comtan, Comtess, Stalevo, Entacapone Orion, Entacapone Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C14H15N3O5
- CAS Number
- 130929-57-6
- Unique Ingredient Identifier
- 4975G9NM6T
- Background
Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the...
- Indication
Used as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose "wearing-off".
- Associated Conditions
- Parkinson's Disease (PD), Wearing Off Effect
- Associated Therapies
- -
Entacapone Combination With Imatinib for Treatment of GIST
- Conditions
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 5
- Registration Number
- NCT04006769
- Locations
- 🇨🇳
Bin Li, MD, Changsha, Hunan, China
Effect of Entacapone on Bodyweight Loss in Obese Population
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2015-02-02
- Lead Sponsor
- Kaichun Wu
- Target Recruit Count
- 30
- Registration Number
- NCT02349243
- Locations
- 🇨🇳
Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
- Conditions
- Interventions
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 80
- Registration Number
- NCT02170376
- Locations
- 🇫🇷
SGS aster, Paris, France
A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- NeuroDerm Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT02096601
- Locations
- 🇮🇱
Tel Aviv Medical Center, Tel Aviv, Israel
🇮🇱Hadassah Medical Center, Jerusalem, Israel
Pilot Study of Entacapone for Methamphetamine Abuse
- Conditions
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 29
- Registration Number
- NCT02058966
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2013-04-25
- Last Posted Date
- 2015-04-01
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 101
- Registration Number
- NCT01840423
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2012-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 67
- Registration Number
- NCT01688089
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon
- Conditions
- Interventions
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 600
- Registration Number
- NCT01568073
- Locations
- 🇵🇹
Bial - Portela & Cª, S.A., S. Mamede do Coronado, Portugal
Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic
- Conditions
- Interventions
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 82
- Registration Number
- NCT01519284
- Locations
- 🇵🇹
Bial - Portela & Cª, S.A., S. Mamede do Coronado, Portugal
Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2010-01-18
- Lead Sponsor
- Uppsala University
- Target Recruit Count
- 10
- Registration Number
- NCT00906828
- Locations
- 🇸🇪
Uppsala University Hospital, Uppsala, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.